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Leptin is a product of the obese (OB) gene secreted by adipocytes in proportion to fat mass. It decreases food intake and increases
energy expenditure by aﬀecting the balance between orexigenic and anorexigenic hypothalamic pathways. Low leptin levels are
responsible for the compensatory increase in appetite and body weight and decreased energy expenditure (EE) following caloric
deprivation. The anorexia-cachexia syndrome is a complication of many chronic conditions including cancer, chronic obstructive
pulmonarydisease,congestiveheartfailure,chronickidneydisease,andaging,wherethedecreaseinbodyweightandfoodintakeis
not followed by a compensatory increase in appetite or decreased EE. Crosstalk between leptin and inﬂammatory signaling known
to be activated in these conditions may be responsible for this paradox. This manuscript will review the evidence and potential
mechanisms mediating changes in the leptin pathway in the setting of anorexia and cachexia associated with chronic diseases.
1.Introdiction
Leptin was discovered in 1994 by Friedman and colleagues
after cloning an obese (OB) gene responsible for obesity in
ob/ob mice [1]. It is a 167 amino acid peptide produced by
adipocytes and it is a member of the adipocytokine family.
Leptin has been noted to play a major role in body mass
regulation by acting in the central nervous system to both
stimulateenergyexpenditureanddecreasefoodintake[2–4].
Named after the Greek word leptos, meaning lean, leptin was
the ﬁrst adipocyte-secreted hormone discovered, proving the
active role of adipocytes in metabolic signaling.
Leptin crosses the blood-brain barrier in a process that is
highly regulated [5–8] and its receptors are found both cen-
trally, in the hypothalamus, and peripherally, in pancreatic
islets, liver, kidney, lung, skeletal muscle, and bone marrow
[9]. Besides its key role on body weight regulation, leptin
aﬀects various metabolic pathways, including growth hor-
mone (GH) signaling [10], insulin sensitivity, and lipogen-
esis [11]. While leptin levels are directly related to adiposity,
thereareseveralotherfactorsresultinginindividualvariabil-
ity. Leptin secretion is regulated by insulin, glucocorticoids,
and catecholamines [3, 12, 13]. Also, females have signiﬁ-
cantly higher levels of leptin than men, for any degree of fat
mass [14]. Along with adiponectin, leptin assists in periph-
eral insulin sensitization independent of body weight [15–
17]. In leptin-deﬁcient (ob/ob) mice, leptin injections led
to dose-dependent reductions in serum glucose levels com-
pared to fed ob/ob controls, before any signiﬁcant change in
body weight occurred [1, 18, 19].
Inactivating mutations of leptin or leptin receptor gene
result in the body’s false perception of starvation and subse-
quenthyperphagia,decreasedenergyexpenditure,andsevere
obesity [20, 21]. In the absence of these mutations and pres-
ence of diet-induced obesity, increased adipose tissue results
in increased leptin levels. A 10% increase in body weight
leads to a 300% increase in serum leptin concentrations
[22]. These elevated leptin levels should lead to decreased
food intake and increased energy expenditure via physical
activity and thermogenesis. Although obese humans have2 International Journal of Peptides
high plasma leptin concentrations, these high levels do not
result in the predicted decrease in appetite. This was initially
thoughttobeduetoleptinresistance.However,anincreasing
body of evidence now suggests central leptin insuﬃciency as
a mechanism. The conventional idea of leptin resistance was
thought to be due to inhibition of leptin signaling pathways
in leptin-responsive neurons, defects downstream of leptin
receptor, and blood-brain barrier (BBB) transport limitation
forleptin[23–27].DecreasedleptintransferviatheBBBdoes
not, however, compromise intracellular signaling in the hy-
pothalamus. Furthermore, centrally administered leptin ef-
fectively decreases the rate of fat accumulation, hyper-
glycemia, insulin resistance, hyperinsulinemia, and progres-
sion to metabolic syndrome in obese rodents [28–30]. The
validity of the concept of leptin resistance has, thus, been
questioned.
Central leptin insuﬃciency due to dietary and lifestyle
changes for extended periods of time has been shown to re-
sult in increased fat accrual, decreased energy expenditure,
hyperinsulinemia, hyperglycemia, neuroendocrine disor-
ders, osteoporosis, and impaired memory [6, 31, 32]. Leptin
permeabilityacrosstheBBBismodulatedbyvariousendoge-
nous factors, including adiposity, daily mealtimes, intrinsic
circadian rhythms governing ingestion behavior, and aging
[5–8]. Transport of leptin to the brain is reduced by fasting
and increased by pretreatment with glucose [33, 34]. Leptin
binding proteins in the blood can aﬀectleptin levels available
for transport to the brain. For example, hepatic C-reactive
protein(CRP),whichisincreasedinobesity,bindsleptinand
limits leptin receptor binding and transport across the BBB
[35,36].Centralleptingenetherapyinobesemiceresultedin
multiple beneﬁts, including normoinsulinemia, euglycemia,
elimination of fatty liver, increased energy expenditure, and
more than doubling of lifespan [32, 37, 38].
Cytokines, such as IL-6 and TNF-α, are increased in obe-
sity and correlate with insulin resistance [39]. After three
weeks of a very low-calorie diet, IL-6 levels decrease in adi-
pose tissue as well as in serum. Furthermore, IL-6 knockout
mice develop obesity at the young age of 6 months [40]. Un-
likeleptin,IL-6hashigherCSFconcentrationsthanserumin
someobese,butotherwisehealthy,men[41].Thepresenceof
increased cytokines, in addition to the hyperleptinemia and
central leptin insuﬃciency, seen in obesity appears to play a
key role in the pathophysiology of metabolic syndrome.
Taken together, the data suggest that the leptin system
m a yb em o r ee ﬃcient in signaling a decrease in fat mass and
lack of nutrients (low leptin state) and triggering a compen-
satory increase in food intake and a decrease in energy ex-
penditure than as a satiety signal when its serum levels are
elevated. Moreover, recent evidence suggests that the neuro-
biology of leptin signaling in obesity appears to involve cen-
tral leptin insuﬃciency, as opposed to the previously postu-
lated notion of leptin resistance. Interestingly, central leptin
administration and gene therapy has successfully improved
energy homeostasis as well as prevented diet-induced obesity
and metabolic syndrome in mice.
The arcuate nucleus (ARC), ventromedial (VMH), dor-
somedial (DMH), and lateral (LH) hypothalamic nuclei are
important regions regulating food intake and energy expen-
diture. Disrupting lesions in the ARC, VMH, and DMH of
rats resulted in hyperphagia and obesity [42]. Moreover, le-
sions in the LH resulted in decreased food intake [43]. Bind-
ing of leptin to its hypothalamic receptors activates a signal-
ingcascadeintheARCthatresultsininhibitionoforexigenic
pathways as indicated by decreased mRNA expression of
neuropeptide Y (NPY) and agouti-related peptide (AgRP),
and stimulation of anorexigenic pathways as suggested by
increases in the mRNA levels of alpha-melanocyte-stimu-
lating hormone (α-MSH) and cocaine and amphetamine-
regulated transcript (CART) [44, 45]. Activation of POMC/
CART-expressing neurons by leptin results in release of α-
MSH, which subsequently binds to melanocotin receptors
(MCRs) and leads to anorexia and increased energy expen-
diture. At the same time, leptin inhibits NPY/AgRP neurons,
which stimulate orexigenic responses and directly inhibits
POMC neuron expression as indicated by POMC mRNA
expression [46, 47]. Interestingly, there is no feedback from
POMCneuronstoNPY/AgRPneurons,revealingthatthede-
fault function of the circuit is to promote food intake [48,
49]. Loss of function mutations of the MC-4R, the most im-
portant melanocortin receptor (MCR), is the most common
genetic etiology of obesity and accounts for 3–5% of severe
human obesity [50, 51], highlighting the relevance of this
pathway in humans. Leptin modiﬁes postsynaptic action of
orexigenic and anorectic signals via the JAK2 (Janus kinase
2)-STAT3 (signal transducer and activator of transcription
3) and PI3K-PDE3B (phosphatidylinositol-3 kinase-phos-
ophodiesterase 3B-cAMP) pathways [52].
Pinto et al. hypothesized that leptin may cause rewiring
of the ARC neural circuit when they found that the NPY/
AgRP and POMC neurons in ob/ob and wild-type mice dif-
fered. Treatment with leptin normalized synaptic density
within six hours, even before leptin levels aﬀected food in-
take.Theseﬁndingsindicatethatleptinmayalsofunctionvia
neural plasticity in the hypothalamus [53]. Another anorec-
tic hypothalamic pathway has been recently characterized in-
volving the protein nesfatin-1 and it appears to be leptin-in-
dependent. Nesfatin-1 targets magnocellular and parvocel-
lular oxytocin neurons as well as nesfatin-1 neurons to stim-
ulate oxytocin release. Oxytocin then activates POMC neu-
rons in the nucleus of the tractus solitaries (NTS) and in-
duces melanocortin-dependent anorexia in leptin-resistant
Zucker-fatty rats. Injecting nesfatin-1 was shown to activate
the PVN and result in leptin-independent melanocortin-
mediated anorexia [54].
In summary, the discovery of ob/ob mice and leptin has
provided evidence that there is hormonal communication
between adipose tissue and the hypothalamus, regulating
food intake and energy metabolism. Leptin controls feeding
viatheARCmelanocortin system,byalteringgenetranscrip-
tion and neural plasticity. The ARC then integrates all the
information it receives and accordingly alters feeding and
metabolismthroughhormonalandneuralpathways.Thehy-
perleptinemic state of obesity has been associated with leptin
resistance or, more likely, central leptin deﬁciency.
Convincing evidence suggest that one of the main roles
of leptin is to signal a state of nutrient deﬁciency and fat
loss. Low leptin levels in this setting will trigger a centrally
mediated, compensatory response leading to increased ap-
petite and food intake, decreased energy expenditure, and,International Journal of Peptides 3
ultimately, weight regain. However, this mechanism does not
appeartobepreservedinmostchronicdiseasesinspiteofthe
weight loss seen. This manuscript will review the evidence
andpotentialmechanismsmediatingchangesinthispathway
inthesettingofanorexiaandcachexiaassociatedwithchron-
ic diseases.
2. Anorexia-CachexiaSyndrome
Anorexia, deﬁned as the loss of desire to eat, despite caloric
deprivation, is frequently seen in patients with advanced
chronic illness [55]. Cachexia, a term derived from Greek
kakos, meaning bad, and hexis, meaning condition, describes
a progressive loss of adipose tissue and lean body mass. In-
creased proteolysis, decreased protein synthesis, and acceler-
ated lipolysis due to high energy demands result in a dra-
matic decline in lean body mass and fat mass and increase in
mortality in this setting [56, 57]. Caloric restriction per se
i n d u c e sal e s ss e v e r ed e g r e eo fw e i g h tl o s sa n dad i ﬀerent
metabolic pattern characterized by decreased energy expen-
ditureandpreservationofleanmassattheexpenseoffatloss.
This suggests that anorexia alone does not cause the extreme
weight loss seen in cachexia. Moreover, nutritional support
does not reverse cachexia [58]. Clinically, ACS presents with
weight loss, decreased appetite, early satiety, muscle atrophy,
and weakness. This process has been observed in various
illnesses, including cancer, chronic heart disease, pulmonary
disease, chronic kidney disease, and aging.
Anorexia-cachexia syndrome appears to be multifacto-
rial,oftenassociatedwiththeunderlyingdiseaseprocess,and
relatedtobothperipheralandcentralneurohormonalsignals
regulating both appetite and energy expenditure. Inﬂamma-
tory cytokines, such as tumor necrosis factor- (TNF-) α, in-
terleukin- (IL-) 1, IL-6, and interferon- (IFN-) γ have been
postulated to play a key pathogenic role in the decreased
food intake and increased energy expenditure seen in most
chronicconditions associatedwiththeanorexia andcachexia
syndrome (ACS) [59]. Increased cytokines in the hypotha-
lamus enhance serotoninergic tone through tryptophan,
resulting in activation of POMC neurons and subsequent
anorexia [60]. IL-1 inhibition in tumor-bearing animals has
been shown to improve appetite and promote weight gain
[61]. The somatomedin pathway, including GH and insulin-
like growth factor-1 (IGF-1), stimulates skeletal muscle pro-
tein synthesis and is inhibited by inﬂammatory cytokines
[62, 63]. In spite of the devastating eﬀect that ACS has in pa-
tients, its pathophysiology is only partially understood and
there are no approved treatments for this condition.
3.CrosstalkbetweenLeptinSignaling
and Inﬂammation
LeptinreceptorsbelongtotheclassIcytokinereceptorfamily
and have similar structure to the signal-transducing subunits
of the IL-6 receptors [64]. Leptin levels decrease with fasting
andincreaseduringthepostprandialphaseafterwards.These
changes are directly correlated with changes in hypothalamic
interleukin- (IL-) 1β mRNA levels, suggesting that leptin has
a proinﬂammatory role centrally [65]. This link between
proinﬂammatory cytokines and leptin has been illustrated
well in animal models. Fasted hamsters treated with the
cytokines tumor necrosis factor- (TNF-) α and IL-1 showed
increased levels of both circulating leptin and leptin mRNA
in adipose tissue. These increases in leptin were associated
with a decline in food intake [66]. This is also supported by
experiments where peripheral leptin administration caused
hypothalamic inﬂammation and central injection of IL-1
receptor (IL-1r) antagonist inhibited the suppression of food
intake caused by central or peripheral injection of leptin
[67]. Mice lacking the main IL-1 receptor responsible for IL-
1 actions showed no reduction in food intake in response
to leptin [68]. Increased inﬂammatory mediators have been
shown to increase hypothalamic POMC mRNA expression
[69]. Administering melanocortin receptor antagonist cen-
trally results in blockade of inﬂammatory anorexia [70].
Leptin levels are signiﬁcantly lower in patients with in-
ﬂ a m m a t o r ys t a t e ss u c ha sc a n c e r[ 71] despite correction for
body fat. These low levels of leptin, however, are not asso-
ciated with greater appetite or lower energy expenditure, as
might be expected. Disturbances in the feedback mechanism
in the hypothalamus and/or release of pro-inﬂammatory
cytokines, such as IL-1, IL-6, and TNF-α, are thought to be
responsible for cachexia in this setting. These circulating
cytokines result in insulin resistance, lipolysis, and loss of
skeletal muscle mass [72]. IL-1 inﬂuences size, duration, and
frequency of meals in rats via hypothalamic signaling [73].
Cytokines also suppress gastric production of the orexigenic
peptide ghrelin that decreases production of inﬂammatory
cytokines TNF-α,I L - 6 ,a n dI L - 1 β.
Nuclear factor-κB( N F - κB), a transcription factor for in-
ﬂammation-related proteins, is activated in the hypotha-
lamus of animal models of infection-associated anorexia.
These models are created by administration of bacterial and
v i r a lp r o d u c t ss u c ha sl i p o p o l y s a c c h a r i d e( L P S )a n dH I V - 1
transactivator protein (Tat). In vitro, NF-κBa c t i v a t i o ns t i m -
ulated POMC transcription, showing the connection of NF-
κB in feeding regulation. Hypothalamic injection of LPS and
Tat showed reductions in food intake and body weight, while
inhibition of NF-κB and melanocortin cancelled these ef-
fects. Moreover, hypothalamic NF- κBi sa c t i v a t e db yl e p t i n
and is involved in leptin-stimulated POMC transcription,
showingthatitmayserveasadownstreamsignalingpathway
of leptin [74]. Paradoxically, inﬂammation is also thought to
play a role in obesity [75]. Obesity in both human [76]a n d
animal models [77] has been associated with increased in-
ﬂammatory markers, including TNF-α and IL-6. In rats and
mice with diet-induced obesity, inﬂammation of both pe-
ripheral tissues and the hypothalamus was noted [78–81].
Blocking hypothalamic inﬂammation signaling via pharma-
cological approach or gene therapy led to a reduction in food
intake and lower body weight in these animals [79, 82].
In summary, the evidence suggests that the central eﬀects
of leptin in suppressing appetite and increasing energy ex-
penditureviaactivationofPOMCneuronsisatleastpartially
dependent upon inﬂammation. Moreover, inﬂammation
may inﬂuence the same pathways aﬀectingappetite andbody
weight independently of leptin.4 International Journal of Peptides
4. LeptininCancerCachexia
Cancer anorexia-cachexia syndrome (Cancer-ACS) is found
in 80% of patients with advanced cancer. It has been shown
to decrease performance status, quality of life, response to
therapy, and survival [56, 57]. Cancer-ACS may account for
up to 20% of cancer deaths [58]. Although the tumor itself is
primarily responsible, treatments such as chemotherapy and
radiation,andassociatedconditionssuchasdepression,pain,
gastrointestinal obstruction, and taste alterations can also
contribute to weight loss [83]. Cancer-ACS appears to be
multifactorial, involving tumor-host interactions that result
in catabolism overwhelming anabolism.
Leptin is thought to play a major role in the patho-
physiology of cancer-ACS. Animal studies have shown that
circulating leptin levels are decreased in the setting of tumor-
induced cachexia, as expected given the decrease in fat mass
seen in this setting [84]. However, mRNA levels of NPY were
decreased and for POMC were increased in the ARC, unlike
what is seen in caloric restriction where low leptin levels
causeactivationofNPYandsuppressionofPOMCpathways.
Levels of phosphorylated signal transducer and activator of
transcription-3(P-Stat3),acentralmoleculeactivatedviathe
leptin receptor signaling pathway, are upregulated in subsets
of α-MSH and NPY positive neurons that are not responsive
toleptin.Thispathwayappearstobeinducedbythecytokine
macrophage inhibitory cytokine-1 (MIC-1) via activation of
the transforming growth factor- (TGF-) β receptor II, sug-
gestingapotentialalternativepathwaythroughwhichMIC-1
could regulate appetite independently of leptin. This is also
supported by the fact that MIC-1 infusion can induce ano-
rexia and weight loss in leptin-deﬁcient mice [85].
Leptin levels are signiﬁcantly decreased in cancer cachex-
iapatientscomparedtobothcancernoncachexiaandhealthy
controls [86, 87]. Proinﬂammatory cytokines, such as TNF-
α, IL-1, and IL-6, have been proposed to cause cachexia in
spite of low circulating leptin due to increased expression
of the hypothalamic leptin receptor [88]. This dysregulation
of the normal feedback loop in cancer cachexia may explain
why a decrease in leptin does not increase appetite or lower
energyexpenditureinpatientswithcancercachexia.Interest-
ingly, leptin was found to be directly associated with appetite
and insulin resistance [87], suggesting that these patients are
resistant to the orexigenic eﬀects of hypoleptinemia. Leptin
also has been postulated as an early marker of disease pro-
gression in advanced ovarian cancer [89]. Moreover, in these
patients, there was a clear correlation between disease stage
and performance status with markers of inﬂammation, such
as IL-6 whereas low leptin levels were more closely associated
with tumor stage and IL-6 levels than BMI.
Giventhelargeroleofproinﬂammatorycytokinesincan-
cer cachexia, the use of anticytokine antibodies and cytokine
receptor antagonists has been investigated as potential ther-
apies. Unfortunately, despite promising experimental data,
clinical trials have not been conclusive. In the Yoshida AH-
130 model, anti-TNF therapy partially reversed metabolic
abnormalities in cachexia [90]. Clinical trials, however,
showed transient improvement at best. In a double-blind-
ed, placebo-controlled, randomized study, pentoxyphylline,
whichinhibitsTNFαtranscription,failedtoshowanybeneﬁt
on cancer cachexia [91]. In small, unrandomized clinical
trials,thalidomide,aTNF-αinhibitor,hasbeenshowntoim-
p r o v es o m ec a n c e r - A C Ss y m p t o m s[ 92]. Anti-inﬂammatory
cytokines, IL-12 and IL-15, have shown some improvement
incancer-ACSintumor-bearinganimals[93,94].Mantovani
etal.performedaphaseIIclinicaltrialwithcyclooxygenase-2
(COX-2) inhibitors in patients with cancer-ACS showing a
signiﬁcant increase in LBM, decrease in TNF-α, and im-
provementinoverallperformancestatus[95].Whetherthese
interventions that blocked inﬂammation had an eﬀect on
leptin or its pathway is not known given that leptin levels or
changes in its downstream mediators were not reported in
these studies.
In summary, cancer anorexia-cachexia syndrome is a
major predictive factor of mortality. In both animal and hu-
man models, circulating leptin levels decrease in the setting
of cancer-ACS. However, this decrease in leptin is not asso-
ciated with a compensatory increase in appetite and food
intake. Animal studies suggest that hypothalamic inﬂamma-
tion may account for the lack of response of leptin targets to
the eﬀects of hypoleptinemia. Although cytokines appear to
play a major role in the development of cancer-ACS via cen-
tral and peripheral eﬀects, preliminary studies targeting this
pathway have not shown convincing evidence of a beneﬁcial
eﬀect.
5.LeptininChronicHeart
Failure-InducedCachexia
The incidence of chronic heart failure is steadily rising and
carries a poor prognosis. Cardiac cachexia is deﬁned as non-
e d e m a t o u sw e i g h tl o s so f>6% of previous normal weight
observed over a period of >6 months and is associated with
poor prognosis [96]. CHF patients with cardiac cachexia
have been noted to have a mortality of 50% at 18 months,
versus17%innoncachecticpatients[97].Variousfactorscan
contribute to the weight loss seen in CHF-induced cachexia,
including malnutrition from medications, metabolic dis-
turbances (i.e., hyponatremia, renal failure), and hepatic
congestion; malabsorption from severe heart failure; or in-
creasednutritional requirements. The basalmetabolic rate in
these patients is increased by 20% [98]. As in other chronic
conditions, inﬂammationhasbeenimplicatedasakeyaspect
of CHF-induced cachexia [99].
Some controversy exists regarding leptin levels in cachec-
tic versus noncachectic CHF patients. While many studies
show lower leptin levels in cachectic patients [10, 100, 101],
as it would be expected with their decreased fat tissue, other
studies report normal levels [102]. These diﬀerences may ex-
istduetosexdistributionandpresenceofcachexiainselected
subjects. When fat tissue was normalized, leptin levels for
both cachectic and noncachectic CHF patients were elevated
in comparison to non-CHF controls [10]. Several groups
have hypothesized that leptin has a cardioprotective role and
that this increase in its levels in the setting of CHF may re-
present a compensatory response rather than simply a mark-
er of fat atrophy [103–105]. This could also explain the fact
that circulating leptin levels directly correlate with NYHAInternational Journal of Peptides 5
class and overall prognosis in this setting. It is also possible
that this increase in leptin is at least partially responsible for
the weight loss and anorexia in CHF patients since an in-
crease in leptin would lead to activation of the melanocortin
system that in turn would cause an increase in energy expen-
diture and a decrease in food intake [106]. This hypothesis
remains to be tested. It is also postulated that hyperleptine-
mia in these patients may be a result of insulin resistance
[107, 108]. Regardless of the reason, this hyperleptinemia in
both cachectic and noncachectic CHF patients suggests that
leptin-mediated decrease in appetite and food intake is not
particularly important in the development of CHF-induced
cachexia.
LeptinmayalsocontributetoCHF-cachexiaandobesity-
related cardiomyopathy by various cardiovascular mecha-
nisms,includingincreasingsympatheticactivityandproduc-
ing vasodilation by an endothelium-dependent mechanism
peripherally. It also promotes inﬂammation, calciﬁcation,
proliferation, and thrombosis in the vasculature [109]. Ani-
mal models, however, do not show any increase in blood
pressure, despite this increase in sympathetic activity [110,
111].Itishypothesizedthatthismaybeduetoleptin’svasod-
ilatory eﬀects via unclear mechanisms [109, 112].
The presence of proinﬂammatory cytokines in this
setting suggests that inﬂammation plays an important role
in the pathogenesis of CHF. Increasing levels of TNF-α,I L - 1 ,
and IL-6, lead to activation of the renin-angiotensin-aldos-
terone-system, improving renal and organ perfusion early
on. However, TNF-α also induces apoptosis and activates
protein breakdown in various tissues, including striate mus-
cle. It also contributes to endothelial dysfunction and subse-
quent decreased blood ﬂow to skeletal muscle, which re-
sults in decreased exercise endurance and nutrient supply
[113]. Plasma TNF-α receptor levels in CHF patients have
been associated with poor- long and short-term prognosis
[114, 115]. Importantly, TNF-α increases the expression of
leptin[66,116].Nocurrenttherapyisapprovedtotargetcar-
diaccachexia.StandardtreatmentofCHFincludingACE-in-
hibitorsandbeta-blockershasbeenshowntoincreaseweight
in CHF patients [96]. However, it appears that increases in
leptin in noncachectic patients with CHF are primarily driv-
en by body weight increases [117].
Although CHF is associated with elevated leptin levels,
these are closely related to the amount of fat tissue; hence,
levels are lower in cachectic individuals compared to non-
cachectic, CHF controls. This elevation in leptin may be due
in part to insulin resistance but a direct cardioprotective ef-
fectofleptinalsohasbeenproposed.Takentogether,thedata
suggests that leptin’s role in this setting is not entirely related
to body weight regulation and that the decreased appetite
and increased energy expenditure seen in CHF-induced
cachexia are more likely due to other factors. There is a scar-
city of therapeutic data on patients with CHF-cachexia, so
little is known about leptin responses to treatment at this
time.
6.LeptininPulmonaryCachexia
Chronic obstructive pulmonary disease (COPD), including
chronic bronchitis, emphysema, asthmatic bronchitis, and
bronchiolitis obliterans, is a leading cause of morbidity and
mortality worldwide. Cachexia has been reported in 20–40%
of COPD patients and is associated with negative prognosis
[118]. Although the increased work of breathing may be
partly responsible for increased energy expenditure, this
alone does not explain the reported weight loss [119, 120]. It
is hypothesized that many diﬀerent pathways are involved in
the pathophysiology of COPD cachexia, including anorexia,
nutritional deﬁciency, hypoxia, increased metabolic rate, in-
activity, sympathetic upregulation, inﬂammation, and ana-
bolic hormone deﬁciency.
Circulating levels of TNF-α and TNF-α production by
peripheral monocytes are increased in patients with pul-
monary cachexia [121, 122]. In both animal and human
models, endotoxin or cytokine (TNF-α or IL-1) administra-
tion produces a dose-dependence increase in serum leptin
levels [66, 123, 124]. However, COPD patients were reported
to have lower leptin levels compared to healthy controls and
these levels correlated well with BMI and percentage body fat
[125].Moreover,thereisalossofcircadianvariationinleptin
levels that may represent alterations in the autonomic ner-
vous system tone. Conversely, serum TNF-α levels were sig-
niﬁcantlyhigherinCOPDpatientscomparedtohealthycon-
trols and did not correlate with leptin levels [126], suggest-
ing that in pulmonary cachexia, leptin levels are physiologi-
cally regulated and are independent of inﬂammatory mark-
ers, such as TNF-α.
In addition to the eﬀects of chronic inﬂammation, it
appears that hypoxia plays a major role in COPD-cachexia.
Leptin-deﬁcientanimalsshowCO2 retentionandrespiratory
depression; leptin administration to these animals increases
minute ventilation and improves lung mechanics suggesting
that an increase in leptin levels in patients with lung disease
may represent a compensatory response to hypoxia [127–
130]. Consistent with this hypothesis, elevated leptin has
been described in hypoxic patients compared to BMI-
matched controls [131]. It has been shown that expression of
the human leptin gene is induced by hypoxia through the
hypoxia-inducible factor-1 (HIF-1) pathway. The introduc-
tion of noninvasive positive airway pressure ventilation
(NIPPV) in patients with severe COPD serves to both de-
crease energy expenditure and hypoxia. Moreover, body
weight signiﬁcantly improved (increased 12%) in patients
with severe COPD and cachexia placed on NIPPV for 1 year
[132]. This elevation in leptin was reversed by improving hy-
poxia, although this was associated with a decrease in fat
accumulation in some studies that may have accounted at
least partially for the changes in leptin.
Insummary,pulmonarycachexialikelyinvolvesmultiple
pathways, including hypoxia and inﬂammation. Circulating
leptin levels are decreased in patients with pulmonary cach-
exia suggesting that the physiologic regulation of leptin is
maintained despite weight loss. Hypoxia also appears to play
a role in leptin expression via the HIF-1 pathway that is re-
versible by correction of hypoxia. Furthermore, correction of
hypoxiaisassociatedwithweightgaininspiteofadecreasein
leptin levels. These ﬁndings are consistent with the hypothe-
sis that leptin plays a role in regulating the respiratory drive
besides its usual role as a metabolic sensor.6 International Journal of Peptides
7.LeptininCKD Cachexia
Chronic kidney disease (CKD) is a common illness associ-
ated with a state of chronic inﬂammation and, oftentimes,
cachexia. CKD-associated cachexia is linked to higher mor-
bidity and mortality [133]. Uremic anorexia appears to be
multifactorial. High plasma levels of insulin, leptin, and
uremic toxins induce MC4-R stimulation to increase energy
expenditure and decrease food intake [134]. Leptin levels are
signiﬁcantly elevated in CKD and ESRD patients and are as-
sociated with markers of poor nutritional status, such as low
serum albumin and hypercatabolism as well as decline in
renal function [135]. Serum leptin concentrations have been
shown to inversely associate with survival in some studies
[136]. In others, leptin was shown to correlate with fat mass
rather than independently aﬀecting food intake or mortality
[137]. The hyperleptinemia seen in dialysis patients may be
due to poor renal clearance, overproduction, or both. It has
been postulated that uremic patients may have an acquired
leptin receptor disorder resulting in central insensitivity or
resistance, similar to obese individuals. Leptin reduces hypo-
thalamic NPY levels and increases sympathetic activity with
hyperinsulinemia, resulting in appetite suppression [138].
Supporting this hypothesis is the observation of increased
sympatheticactivity,viaelevateddopamine,norepinephrine,
and serotonin levels, found in uremic patients [139]. Ele-
vated serum acute phase reactants, including C-reactive pro-
tein(CRP)andseveralcytokines,mostprominentlyIL-6and
TNF-α, are found in CKD patients and may be associated
with reduced appetite in dialysis patients [140]. Increased
inﬂammation in renal failure is multifactorial, and possible
factors include decreased renal clearance and increased pro-
duction of proinﬂammatory cytokines [141, 142]. The medi-
ators of inﬂammation act on the central nervous system to
alter both appetite and metabolic rate [143, 144].
The administration of AgRP to mice with CKD resulted
in increased food intake, normalization of basal metabolic
rate, and increases in total body weight and lean body mass,
independent of caloric or protein intake. Also, studies in db/
db mice show that the lack of leptin receptor is protective
against CKD-induced cachexia. Furthermore, manipulation
of leptin’s downstream mediators in the hypothalamus, MC4
byeither genedeletion orby using antagonists of its receptor,
conﬁrms the relevance of this pathway in mediating anorexia
and weigh loss in the setting of CKD [145].
A cross-sectional study of 217 hemodialysis patients fol-
lowed for 31 months showed that those in the lowest tertile
of ghrelin levels were the oldest and had the highest BMI,
and highest CRP and leptin levels. These patients all had in-
creased mortality risk, despite adjustment for age, gender,
and dialysis history. Moreover, those in this group with pro-
tein-energy wasting had the highest all-cause and cardio-
vascular mortality risk (hazards ratios 3.34 and 3.54, resp.)
[151]. In the setting of CKD, there is the opportunity to
manipulate leptin levels not only by administering recom-
binant leptin but also by removing leptin from circulation
using super-ﬂux polysulfone dialyzers. van Tellingen et al.
tried such approach and although leptin levels were signiﬁ-
cantly reduced, no other parameters such as appetite or body
composition were examined [152, 153]. Therefore, the eﬀec-
tiveness of this intervention remains unknown.
Taken together, the evidence shows that CKD and ESRD-
induced cachexia are associated with poor prognosis. Ele-
vated levels of inﬂammatory mediators and leptin are likely
results of decreased renal clearance and disease-related in-
ﬂammation. Activation of the melanocortin system by leptin
is key in the pathophysiology of CKD cachexia. Further stud-
ies to explore the eﬃcacy of therapeutic options, including
polysulfone dialyzers to lower leptin levels, are needed to
determine the role of leptin in this setting.
8.LeptininAging
Weight loss in the geriatric population is a strong predictor
of morbidity and mortality [154]. Normal aging involves a
declineinappetite,decreaseinleanbodymass,increaseinfat
mass, and decrease in energy expenditure [155]. Aging has
signiﬁcant eﬀects on energy homeostasis and dysregulation
of adipokines, including leptin. These eﬀects appear to be
mediated at least in part by a decrease in the tone of the
orexigenic AgRP/NPY pathway, an increase of the anorexi-
genic CART/POMC pathway, and failure of these pathways
in responding to caloric restriction.
Elevatedcirculatingleptinlevelswithdecreasedhypotha-
lamic leptin responsiveness have been found in both animal
and human models of aging [146]. Using a rodent model
of aging, Wolden-Hanson showed that caloric restriction in
aged Brown Norway rats failed to induce a compensatory in-
creaseinappetiteafterrefeeding,unlikewhatisseeninyoung
animals [147]. Leptin levels are increased in aged animals
parallelingchangesinfatmassbutfailtodecreaseinresponse
tofasting,suggestingthathyperleptinemiamaycontributeto
this energy balance dysregulation and play a causative role in
the poor tolerance of aged individuals to catabolic condi-
tions. Also, leptin resistance has been proposed as one of the
alterations seen in the elderly [156]. Hence, hyperleptinemia
may be a compensatory mechanism to overcome the im-
paired leptin action in the brain. Uptake of leptin in the hy-
pothalamus is signiﬁcantly lower in old animals [157]. In
aged rats, leptin administration does not suppress appetite,
hypothalamicNPYexpression,circulatingleptinlevels,orob
mRNA levels in white adipose tissue to the same extent as
in young animals [148]. Although expression of the leptin
receptor was not investigated in this report, others have
shownadecreaseinexpressionofthelongformofthisrecep-
tor during aging [157]. Downstream of leptin, abnormalities
in other hypothalamic neuropeptides have been reported as
well. Transcript mRNA expression of the orexigenic peptides
NPY and AgRP decreases and fails to increase in response to
caloric restriction [149, 158]; while CART mRNA expression
increases with aging. Although response to exogenous AgRP
appears to be maintained, response to NPY administration
was signiﬁcantly blunted in aged animals [159].
Previous studies have shown protective eﬀects of fat
mass on morbidity and mortality in the geriatric population
[160]. Lipoatrophy and lipodystrophy in aging have been
associated with dysregulation of adipokines and, subse-
quently, metabolic derangements such as insulin resistance,International Journal of Peptides 7
Table 1: Summary of markers of appetite regulation in various cachectic states.
Condition Appetite Body Weight Circulating
Leptin Levels
POMC/α-MSH
hypothalamic levels
NPY/AgRP
hypothalamic levels
Circulating
inﬂammatory
markers
Hypothalamic
inﬂammatory
markers
References
Cancer
cachexia
↓∗# ↓∗# ↓∗# ↑∗ ↓∗ ↑∗# ↑∗ [60,84–87]
CHF-induced
cachexia
↓∗# ↓∗# ↑∗# unknown unknown ↑∗# unknown [10, 99–
102, 115]
Pulmonary
cachexia
↓∗# ↓∗# ↓∗# unknown unknown ↑∗# unknown [121, 122,
124–126]
CKD cachexia ↓∗# ↓∗# ↑∗# unknown unknown ↑∗# unknown
[135, 137,
139, 140,
142, 145]
Aging cachexia ↓∗# ↓∗# ↓∗# ↑∗ ↓∗ ↑∗# unknown [146–150]
#—supported by human model data; ∗—supported by animal model data.
NPY/AgRP  POMC/CART  
Arcuate nucleus  
Neuron
Adipose tissue 
 Leptin 
Food 
intake  
Energy  
expenditure   MC-4R
Cytokines
Cancer, 
CHF, COPD,  
CKD, aging
α-MSH
Figure 1: Summrary of the eﬀects of peripheral hormones on hypothalamic regulation of food intake and energy expenditure. NPY =
neuropeptide Y; AgRP = Agoui-relaed peptide; POMC = pro-opiomelacortin; CART = cocaine-amphetamine-related peptide; α-MSH =
alpha-melanocyte-stimulating hormone; MC-4R = type-4 melanocortin receptor.
dyslipidemia,metabolicsyndrome,hypertension,andhyper-
glycemia. Centenarians, models of health and longevity, had
been reported to exhibit preserved insulin sensitivity and
intact adipokine proﬁles. Studying this population revealed
that poor prognosis was associated with dysregulated adi-
pokines, including leptin levels inappropriately low for fat
mass [161]. Leptin concentrations in 19 elderly patients with
protein-energy malnutrition were signiﬁcantly lower than
their age-matched controls. However, others have reported
an increase in leptin levels in aged individuals even after
adjusting for fat mass [162]. It has also been shown that the
there are increased levels of IL-6 and CRP in aging [150].
Studies in obese patients have suggested an association be-
tween hypothalamic inﬂammation and decreased leptin ac-
tionviapersistenceactivationofthemelanocortinsystem;no
studies, however, have been performed in the elderly [69,
163]. Functional status, anthropometry, and serum markers
of nutrition and inﬂammation, including leptin and CRP, in
seventy elderly patients versus controls revealed that those
with the lowest functional status and highest frailty indices
displayed features of cachexia. Moreover, they had low leptin
levels, appropriate for their low body fat, as well as high CRP
and IL-6 levels [164]. This suggests that the mechanism for
cachexia in the elderly may involve disrupted hypothalamic
feedback of leptin from the eﬀects of proinﬂammatory cyto-
kines like other chronic inﬂammatory states.
In summary, weight loss in the geriatric population is
associated with higher mortality. In normal aging, fat mass
is increased and hyperleptinemia arises. Despite these high
levels of circulating leptin, however, there appears to be de-
creased leptin action and subsequently no decrease in appe-
tite, similar to obese individuals. Moreover, a failed hypotha-
lamicresponsetocaloricrestrictionappearstoberesponsible
for the poor tolerance of the elderly to catabolic stress.
Elderly patients with cachexia tend to have elevated inﬂam-
matory markers and low leptin levels, both correlating with
worsened prognosis.8 International Journal of Peptides
9. Conclusion
Leptin,aproductoftheobesegenesecretedbyadiposetissue,
acts centrally to suppress appetite and increase thermogene-
sis by activating the POMC neurons in the arcuate nucleus
and triggering the release of α-MSH from POMC axon ter-
minalsandsubsequentlyactivatingMC4-R(Figure 1).More-
over, the NPY and AgRP-producing neurons of the arcuate
nucleus,whicharesuppressedbyleptin,canantagonizethese
anorexigenic melanocortin cells. Consequently, low levels of
leptin cause an increase in appetite and reduce energy ex-
penditure.
Cachexia is a unique process characterized by depletion
of adipose tissue and lean body mass found in various
chronic diseases often accompanied by anorexia. Anorexia-
cachexia can be seen in cancer, CHF, COPD, CKD, and aging
(Table 1). All of these conditions are associated with elevated
inﬂammatory markers such as TNF-α, IL-6, IL-2, and IL-1β.
These inﬂammatory markers may regulate hypothalamic
feedback mechanisms and are thought to contribute to the
development of cachexia. Leptin receptors belong to the class
I cytokine family and there is crosstalk between leptin sig-
naling and inﬂammation. This crosstalk could explain why,
despitelowlevelsofleptininchronicinﬂammatoryprocesses
such as cancer, COPD, and aging, patients do not have the
expected increased appetite or lower energy expenditure.
Cancer, COPD, and aging-associated cachexia are all as-
sociated with low leptin levels, in spite of low appetite and
elevated energy expenditure suggesting a state of resistance
to the eﬀects of hypoleptinemia. On the contrary, elevated
levels have been noted in CKD- and CHF-induced cachexia.
In CHF-induced cachexia, the reason for this elevation is
unclear but there is no association with weight or fat mass
change or with appetite suggesting that leptin may have a
diﬀerent function in this setting and that it likely does not
play a major role in the ensuing cachexia. In CKD and ESRD,
circulating levels of leptin and inﬂammatory agents are like-
lyelevatedduetopoorrenalclearancebutthereisnoassocia-
tion with the degree of weight loss or anorexia.
Given the key role that inﬂammation appears to play in
the pathogenesis of leptin-mediated cachexia, therapeutic
intervention with anti-inﬂammatory drugs may prove to be
beneﬁcial in restoring sensitivity to the eﬀect of hypoleptine-
mia in ACS. COX-2 inhibitors have shown some promise in
patients with cancer cachexia. In the setting of uremic cach-
exia, polysulfone dialysers decrease leptin levels but more
studies are needed to evaluate the eﬀect of this intervention
on appetite and weight parameters. As we gain more in-
sight into the pathophysiology of cachexia, the therapeutic
possibilitiesincrease.Furtherinvestigationsintoanti-inﬂam-
matory drugs, appetite stimulants, and immunomodulators
in these various conditions are warranted.
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